Invasive streptococcal infections

Journal of Infection and Chemotherapy

Volumn 7, Issue 2, 2001, Pages 69-80

  Stevens, D L ^a  

^a Boise VA Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CLINDAMYCIN; ERYTHROMYCIN; IMMUNOGLOBULIN; M PROTEIN; PENICILLIN DERIVATIVE; VACCINE;

ANTIBIOTIC THERAPY; BACTEREMIA; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; HUMAN; LYMPHANGITIS; NONHUMAN; PATHOGENESIS; PUERPERAL INFECTION; RESPIRATORY TRACT INFECTION; REVIEW; SEROTYPE; SOFT TISSUE INFECTION; STREPTOCOCCUS INFECTION; TOXIC SHOCK SYNDROME;

EID: 0034935411     PISSN: 1341321X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s101560100012     Document Type: Review

References (122)

1. Invasive group A streptococcal disease in the Netherlands: Evidence for a protective role of anti-exotoxin A antibodies
2. An outbreak of invasive group A streptococcal disease associated with high carriage rates of the invasive clone among school-aged children
3. Streptococcal toxic shock syndrome: Spectrum of disease, pathogenesis and new concepts in treatment
4. Streptococcal serogroup A epidemic in Norway 1987-1988
5. Invasive group A streptococcal infections: T1Mi isolates expressing pyrogenic exotoxins A and B in combination with selective lack of toxin-neutralizing antibodies are associated with increased risk of streptococcal toxic shock syndrome
6. Protective immunity to the group A streptococcus may be only strain specific
7. Hetereogeneous opsonic activity of convalescence serum against M-1 strains of group A Streptococci (GAS)
8. Epidemiologic analysis of group A streptococcal serotypes associated with severe systemic infections, rheumatic fever, or uncomplicated pharyngitis
9. Genetic and phenotypic diversity among isolates of Streptococcus pyogenes from invasive infections
10. Production of NADase in clinical isolates of Streptococcus pyogenes
11. Diphosphopyridine nucleotidase as an extracellular product of streptococcal growth and its possible relationship to leukotoxicity
12. Application of a new method for detecting streptococcal nicotinamide adenine dinucleotide glycohydrolase to various M types of Streptococcus pyogenes
13. NAD+-glycohydrolase productivity of haemolytic streptococci assayed by a simple fluorescent method and its relation to T serotype
14. The NAD-glycohydrolase (nga) gene of Streptococcus pyogenes
15. Mole-cular epidemiology of nga and NAD glycohydrolase/ADP-ribosyltransferase activity among Streptococcus pyogenes causing streptococcal toxic shock syndrome
16. Reappearance of scarlet fever toxin A among streptococci in the Rocky Mountain West: Severe group A streptococcal infections associated with a toxic shock-like syndrome
17. Invasive group A streptococcus infections
18. Complications of varicella I. Their occurrence among 2534 patients
19. Group A beta-hemolytic streptococcal bacteremia: Historical overview, changing incidence, and recent association with varicella
20. Treatment of patients with a history of recurrent tonsillitis due to group A β-hemolytic streptococci
21. Peritonsillar abscess: Incidence, current management practices, and a proposal for treatment guidelines
22. Human endothelial cells in culture produce platelet-activating factor (1-alkyl-2-acetyl-sn-glycero-3-phosphocholine) when stimulated with thrombin
23. The writings of Oliver Wendell Holmes
24. Fatal infections by haemolytic streptococcus group B
25. The return of life-threatening puerperal sepsis caused by group A streptococci
26. An epidemic of "childbed fever"
27. Life-threatening puerperal sepsis caused by group A streptococci
28. Puerperal sepsis due to infected episiotomy wound
29. Puerperal sepsis caused by streptococcus group A with a severe form of progression like "toxic shock-like syndrome"
30. A new type of fulminant group A streptococcal infection in obstetric patients: Report of two cases
31. Nosocomial group A streptococcal infections associated with asymptomatic health-care workers - Maryland and California
32. Zur Kenntnis und Behandlung des nekrotisierenden Erysipels
33. Hemolytic streptococcus gangrene
34. Streptococcal myositis
35. Peracute spontaneous streptococcal myositis. A report on two fatal cases with review of literature
36. Aspects of pathogenesis of serious group A streptococcal infections in Sweden, 1988-1989
37. Severe invasive group A streptococcal infections in Ontario, Canada: 1987-1991
38. Streptococcal necrotizing myositis - A rare entity: A report of two cases
39. Spontaneous gangrenous myositis induced by Streptococcus pyogenes: Case report and review of the literature
40. Streptococcal infections in skin and soft tissues
41. Spontaneous, nontraumatic gangrene due to Clostridium septicum
42. Experimental approach to the problem of treatment failure with penicillin. I. Group A streptococcal infection in mice
43. The Eagle effect revisited: Efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis
44. Changing epidemiology of group A streptococcal infection in the USA
45. Familial transmission of a serious disease-producing group A streptococcus clone: Case reports and review
46. Spread of serious disease-producing M3 clones of group A streptococcus among family members and health care workers
47. Transmission of Streptococcus pyogenes causing toxic shock-like syndrome among family members and confirmation by DNA macrorestriction analysis
48. Invasive group A streptococcal infections in Ontario, Canada
49. Outbreak of invasive group A streptococcal infections in a nursing home. Lessons on prevention and control
50. Invasive group A streptococcal (GAS) serotype M-1 outbreak in a long-term care facility (LTCF) with mortality
51. Septic shock induced by group A streptococcal infections: Clinical and therapeutic aspects
52. Association of exotoxin-producing group A streptococci and severe disease in children
53. Molecular analysis of pyrogenic exotoxins from Streptococcus pyogenes isolates associated with toxic shock-like syndrome
54. Streptococcus pyogenes causing toxic-shock-like syndrome and other invasive diseases: Clonal diversity and pyrogenic exotoxin expression
55. Correspondence: Group A streptococcal infections and a toxic shock-like syndrome
56. A novel superantigen isolated from pathogenic strains of Streptococcus pyogenes with aminoterminal homology to staphylococcal enterotoxins B and C
57. Cloning, characterization and overexpression of a Streptococcus pyogenes gene encoding a new type of mitogenic factor
58. Superantigenic properties of the group A streptococcal exotoxin SpeF (MF)
59. Group A streptococci efficiently invade human respiratory epithelial cells
60. High-frequency intracellular invasion of epithelial cells by serotype M1 group A streptococci: M1 protein-mediated invasion and cytoskeletal rearrangements
61. Invasion and survival of Streptococcus pyogenes in eukaryotic cells correlates with the source of clinical isolates
62. Comparison of adherence to and penetration of a human laryngeal epithelial cell line by group A streptococci of various M protein types
63. Capsular hyaluronic acid of group A streptococci hampers their invasion into human pharyngeal epithelial cells
64. Effect of group A streptococcal cysteine protease on invasion of epithelial cells
65. Role of group A streptococcal virulence factors in adherence to keratinocytes
66. Inactivation of the cysteine protease SpeB affects hyaluronic acid capsule expression in group A streptococci
67. Fibronectin-binding protein of Streptococcus pyogenes: Sequence of the binding domain involved in adherence of streptococci to epithelial cells
68. Protein F, a fibronectin-binding protein, is an adhesin of the group A streptococcus Streptococcus pyogenes
69. Streptococcus pyogenes protein F promotes invasion of HeLa cells
70. Protein F1 is required for efficient entry of Streptococcus pyogenes into epithelial cells
71. Immunoglobulins to group A streptococcal surface molecules decrease adherence to and invasion of human pharyngeal cells
72. Tumor necrosis factor-alpha and interleukin-1 alpha decrease the adherence of Streptococcus pyogenes to cultured keratinocytes
73. Protective immune response against Streptococcus pyogenes in mice after intranasal vaccination with the fibronectin-binding protein SfbI
74. Distribution and antigenicity of fibronectin binding proteins (SfbI and SfbII) of Streptococcus pyogenes clinical isolates from the Northern Territory, Australia
75. Toxic shock syndrome-associated staphylococcal and streptococcal pyrogenic toxins are potent inducers of tumor necrosis factor production
76. Cytokine production by human mononuclear cells in response to streptococcal exotoxins
77. Similar cytokine induction profiles of a novel streptococcal exotoxin, MF, and pyrogenic exotoxins A and B
78. Cytokine production by murine cells activated by erythrogenic toxin type A superantigen of Streptococcus pyogenes
79. The production of pyrogenic exotoxins by group A streptococci
80. Characterization of a superantigen from a pathogenic strain of Streptococcus pyogenes
81. Streptococcal toxic shock syndrome: Synthesis of tumor necrosis factor and interleukin-1 by monocytes stimulated with pyrogenic exotoxin A and streptolysin O
82. Cellular and biochemical responses of human T lymphocytes stimulated with streptococcal M protein
83. Selective depletion of Vβ-bearing T cells in patients with severe invasive group A streptococcal infections and streptococcal toxic shock syndrome
84. Gram-positive shock
85. Cytokine induction by viable group A streptococci: Suppression by streptolysin O
86. Comparative study of cytokine release by human peripheral blood mononuclear cells stimulated with Streptococcus pyogenes superantigenic erythrogenic toxins, heat-killed streptococci and lipopolysaccharide
87. Superantigens associated with staphylococcal and streptococcal toxic shock syndromes are potent inducers of tumor necrosis factor beta synthesis
88. Cleavage of interleukin 1β (IL-1β) precursor to produce active IL-1β by a conserved extracellular cysteine protease from Streptococcus pyogenes
89. Activation of a 66-kilodalton human endothelial cell matrix metalloprotease by Streptococcus pyogenes extracellular cysteine protease
90. A virulence regulon in Streptococcus pyogenes
91. Clonal basis for resurgence of serious Streptococcus pyogenes disease in the 1980s
92. Group A streptococcal pyrogenic exotoxin: Pyrogenicity, alteration of blood-brain barrier, and separation of sites for pyrogenicity, and enhancement of lethal endotoxin shock
93. Macrophage hyperreactivity to endotoxin induced by streptococcal pyrogenic exotoxin in rabbits
94. Pretreatment with either endotoxin (LPS), tumor necrosis factor α (TNFα) or streptococcal pyrogenic exotoxin A (SPEA) protects mice from lethal streptococcal infection
95. Streptococcal pyrogenic exotoxin A release, distribution, and role in a murine model of fasciitis and multiorgan failure due to Streptococcus pyogenes
96. Streptococcal pyrogenic exotoxin A (SPE A) can augment neutrophil recruitment to sites of inflammation
97. Group A streptococcal bacteremia: The role of tumor necrosis factor in shock and organ failure
98. Identification of DNA CpG sequence motifs in group A streptococcal virulent genes that preferentially stimulate human lymphocytes: Evidence for differential host responsiveness
99. The role of nitric oxide in experimental murine sepsis due to pyrogenic exotoxin A-producing Streptococcus pyogenes
100. Allele substitution of the streptokinase gene reduces the nephritogenic capacity of group A streptococcal strain NZ131
101. Reduced virulence of group A streptococcal Tn916 mutants that do not produce streptolysin S
102. Genetic locus for streptolysin S production by group A streptococcus
103. Association of penicillin tolerance with failure to eradicate group A streptococci from patients with pharyngitis
104. Failure of penicillin to eradicate group A streptococci during an outbreak of pharyngitis
105. Role of beta-lactamase-producing bacteria in the failure of penicillin to eradicate group A streptococci
106. Streptococcal toxic shock syndrome
107. Streptococcus pyogenes and the toxic shock syndrome
108. Invasive group A streptococcal infection: New concepts in antibiotic treatment
109. Penicillin binding protein expression at different growth stages determines penicillin efficacy in vitro and in vivo: An explanation for the inoculum effect
110. The in vitro antibacterial activity of ceftriaxone against Streptococcus pyogenes is unrelated to penicillin-binding protein 4
111. Persistent acylation of high-molecular weight penicillin binding proteins by penicillin induces the post antibiotic effect in Streptococcus pyogenes
112. Effect of antibiotics on toxin production and viability of Clostridium perfringens
113. Potentiation of opsonization and phagocytosis of Streptococcus pyogenes following growth in the presence of clindamycin
114. Antibiotic effects on bacterial viability, toxin production, and host response
115. Improved outcome of clindamycin compared with beta-lactam antibiotic treatment for invasive Streptococcus pyogenes infection
116. Intravenous immunoglobulin therapy for toxic shock syndrome
117. Necrotising fasciitis
118. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome. A comparative observational study
119. Clusters of invasive group A streptococcal infections in family, hospital, and nursing home settings
120. Transmission of 'toxic strep' syndrome from an infected child to a firefighter during CPR
121. Wound infections due to group A streptococcus traced to a vaginal carrier
122. Prevention of invasive group A streptococcal diseases among household contacts of case-patients: Is prophylaxis warranted?